Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal
Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p.m. ET to discuss its reverse stock split proposal. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders support the proposal, which aims to regain Nasdaq compliance.
The company's management team will address stockholder questions during the event, with investors able to submit questions in advance. Stockholders of record as of July 29, 2025, can vote on the proposal until September 4, 2025.
[]Vaxart (OTCQX: VXRT), una societ脿 biotech in fase clinica che sviluppa vaccini ricombinanti orali in formato pillola, terr脿 un incontro virtuale con gli azionisti il 20 agosto 2025 alle 16:30 ET per discutere la proposta di raggruppamento azionario (reverse stock split). Le principali societ脿 di consulenza per il voto per procura, ISS e Glass Lewis, hanno raccomandato agli azionisti di sostenere la proposta, finalizzata a ristabilire la conformit脿 con il Nasdaq.
Il management risponder脿 alle domande degli azionisti durante l'evento e gli investitori potranno inviare quesiti in anticipo. Gli azionisti registrati alla data del 29 luglio 2025 potranno votare la proposta fino al 4 settembre 2025.
Vaxart (OTCQX: VXRT), una biotecnol贸gica en fase cl铆nica que desarrolla vacunas recombinantes orales en pastilla, celebrar谩 un encuentro virtual con accionistas el 20 de agosto de 2025 a las 4:30 p.m. ET para tratar su propuesta de consolidaci贸n inversa de acciones (reverse stock split). Las principales firmas de asesoramiento de voto, ISS y Glass Lewis, han recomendado a los accionistas apoyar la propuesta, que busca recuperar el cumplimiento con Nasdaq.
El equipo directivo responder谩 preguntas de los accionistas durante el evento y los inversores podr谩n enviar preguntas por adelantado. Los accionistas registrados a fecha de 29 de julio de 2025 podr谩n votar la propuesta hasta el 4 de septiembre de 2025.
Vaxart (OTCQX: VXRT)電� 瓴疥惮鞖� 鞛“頃� 頃勲氚膘嫚(鞎岇暯順�)鞚� 臧滊皽 欷戩澑 鞛勳儊 雼硠 氚旍澊鞓ろ厤 須岇偓搿�, 2025雲� 8鞗� 20鞚� 鞓ろ泟 4鞁� 30攵�(霃欕秬鞁滉皠)鞐� 欤检＜霌れ潉 雽�靸侅溂搿� 毽矂鞀� 鞀ろ啞 鞀ろ攲毽�(reverse stock split) 鞝滌晥鞐� 雽�頃� 雲检潣頃橂姅 頇旍儊 臧勲嫶須岆ゼ 臧滌禍頃╇媹雼�. 欤检殧 鞚橁舶甓� 鞛愲靷澑 ISS鞕� Glass Lewis電� 鞚� 鞝滌晥鞐� 雽�頃� 欤检＜霌れ潣 歆�歆�毳� 甓岅碃頄堨溂氅�, 鞚措姅 雮橃姢雼� 攴滌爼 欷�靾橂ゼ 須岆车頃橂牑電� 氇╈爜鞛呺媹雼�.
瓴届榿歆勳潃 頄夓偓鞐愳劀 欤检＜霌れ潣 歆堧鞐� 雼惦硛頃� 鞓堨爼鞚措┌, 韴瀽鞛愲摛鞚� 靷爠鞐� 歆堧鞚� 鞝滌稖頃� 靾� 鞛堨姷雼堧嫟. 2025雲� 7鞗� 29鞚� 旮办 氇呺秬鞐� 霌彪霅� 欤检＜電� 2025雲� 9鞗� 4鞚�旯岇 頃措嫻 鞎堦贝鞐� 雽�頃� 韴憸頃� 靾� 鞛堨姷雼堧嫟.
Vaxart (OTCQX: VXRT), une soci茅t茅 de biotechnologie en phase clinique d茅veloppant des vaccins recombinants oraux sous forme de comprim茅, tiendra une discussion virtuelle avec les actionnaires le 20 ao没t 2025 脿 16h30 (heure de l'Est) pour expliquer sa proposition de reverse stock split (regroupement d'actions). Les principaux cabinets de conseil en vote, ISS et Glass Lewis, ont recommand茅 aux actionnaires d'approuver la proposition, qui vise 脿 r茅tablir la conformit茅 avec le Nasdaq.
L'茅quipe de direction r茅pondra aux questions des actionnaires pendant l'茅v茅nement, et les investisseurs pourront soumettre des questions 脿 l'avance. Les actionnaires enregistr茅s au 29 juillet 2025 pourront voter sur la proposition jusqu'au 4 septembre 2025.
Vaxart (OTCQX: VXRT), ein Biotech-Unternehmen in der klinischen Phase, das orale rekombinante Tabletten-Impfstoffe entwickelt, wird am 20. August 2025 um 16:30 Uhr ET eine virtuelle Aktion盲rs鈥慒ireside鈥慍hat veranstalten, um seinen Vorschlag f眉r einen Reverse鈥慡plit zu er枚rtern. Die f眉hrenden Stimmrechtsberater ISS und Glass Lewis haben den Aktion盲ren empfohlen, den Vorschlag zu unterst眉tzen, der die Wiederherstellung der Nasdaq鈥慍ompliance zum Ziel hat.
Das Management wird w盲hrend der Veranstaltung Fragen der Aktion盲re beantworten; Anleger k枚nnen Fragen im Voraus einreichen. Aktion盲re, die am 29. Juli 2025 als Eigent眉mer verzeichnet sind, k枚nnen bis zum 4. September 2025 眉ber den Vorschlag abstimmen.
- None.
- Company has been delisted from Nasdaq and currently trades on OTCQX
- Reverse stock split indicates potential share price challenges
Insights
Vaxart's reverse split proposal aims to regain Nasdaq listing, signaling financial challenges despite receiving proxy advisor support.
Vaxart's announcement reveals significant corporate governance developments as the company seeks shareholder approval for a reverse stock split. Currently trading on the OTCQX market (not Nasdaq), this critical vote aims to help the company regain Nasdaq compliance - a clear indication Vaxart has fallen below Nasdaq's continued listing requirements.
The endorsements from ISS and Glass Lewis - respected independent proxy advisory firms whose recommendations carry substantial weight with institutional investors - suggest the proposal has merit from a governance perspective. These firms typically support reverse splits only when they see a legitimate strategic rationale rather than mere cosmetic share price manipulation.
A reverse split mathematically increases the per-share price by reducing the number of outstanding shares, but doesn't fundamentally change company value. However, for Vaxart, Nasdaq relisting offers significant benefits: improved liquidity, broader access to capital, increased analyst coverage, and enhanced institutional investor interest.
The management's decision to host a fireside chat rather than simply collecting proxy votes demonstrates recognition of retail investor concerns. Reverse splits often face skepticism as they're frequently associated with struggling companies and can attract short sellers post-implementation.
Vaxart's current OTCQX status significantly limits its access to capital at a time when, as a clinical-stage biotech without marketable products, continued funding is essential for advancing its oral vaccine platform through expensive clinical trials.
- ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal -
- Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT -
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform,听today announced that members of the senior management team will participate in a virtual stockholder fireside chat on Wednesday, August 20, 2025 at 4:30 p.m. ET / 1:30 p.m. PT.
鈥淥ur leadership team is excited for this opportunity to connect with our stockholders directly. This fireside chat is a chance for us to answer many of the frequently asked questions from our stockholders, particularly around the rationale for a reverse stock split and the need to regain Nasdaq compliance,鈥� said Steven Lo, Chief Executive Officer of Vaxart.
A live webcast of the fireside chat will be available on the Company鈥檚 website at or by听.
Investors may submit written questions in advance of the conference call to or through the webcast portal. A replay of the webcast will be available on the Company鈥檚 website at following the conclusion of the event.
Leading independent proxy advisory firms, Institutional Shareholder Services (鈥淚SS鈥�) and Glass Lewis, recommend that stockholders support the reverse stock split proposal.
Vaxart听encourages all stockholders of record on听July 29, 2025,听who have not yet voted to do so by听11:59 p.m. Eastern Time听on听September 4, 2025.
If you have any questions or need assistance with voting, please contact Vaxart鈥檚 proxy solicitation firm:
Campaign Management, LLC
Toll-Free: 1-855-264-1527
贰尘补颈濒:听听
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart鈥檚 development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart鈥檚 first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
| Vaxart听Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners 听 |
| [email protected] 听听 |
| (646) 871-8481 |
This press release was published by a CLEAR庐 Verified individual.
FAQ
When is Vaxart (VXRT) hosting its stockholder fireside chat about the reverse stock split?
Why is Vaxart (VXRT) proposing a reverse stock split?
How can Vaxart (VXRT) stockholders participate in voting for the reverse stock split?
What does Vaxart (VXRT) do as a company?
How can investors access Vaxart's stockholder fireside chat?
